Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Chlamydia screening: doubts on cost effectiveness

GP register-based population screening programmes for chlamydia infection are poor value for money, according to a new economic model.

GP register-based population screening programmes for chlamydia infection are poor value for money, according to a new economic model.

It would cost about £22,300 to prevent one major outcome ­ most commonly pelvic inflammatory disease leading to hospital admission
Having the disease would have to be equivalent to being in a state equivalent to death for nearly nine months for a GP register-based programme to meet NICE's cost-effectiveness threshold of £30,000 per QALY, said researchers from the universities of Birmingham and Bristol.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say